IGC Pharma Reports Revenue Decline to $191,000 Amid Strategic Focus on Clinical Trials

IGC Pharma, Inc. reported its financial results for the quarter ending September 30, 2025, revealing a revenue of approximately $191,000, a decrease from $412,000 in the same period last year. The decline in revenue is attributed to a strategic focus on advancing its lead therapeutic candidate, IGC-AD1, which is currently in Phase 2 clinical trials for treating agitation in Alzheimer’s dementia. The company also experienced a significant reduction in production and fulfillment activities due to the transition of its Vancouver manufacturing facility to a new owner under a favorable contract. The gross profit for the quarter was $99,000, reflecting a gross margin of 52%, compared to 48% in the prior year.

In terms of expenses, IGC Pharma's selling, general, and administrative (SG&A) costs rose to $1.4 million, a 35% increase from $1.0 million in the previous year, primarily due to higher marketing and corporate expenses. Research and development (R&D) expenses also increased by 73% to approximately $1.6 million, driven by the ongoing Phase 2 trials and preclinical studies on other small molecule assets. The company reported an operating loss of $2.9 million for the quarter, compared to a loss of $1.8 million in the same period last year. However, other income surged to $1.1 million, largely due to profits from the sale of assets, resulting in a net loss of $1.8 million for the quarter.

Comparatively, for the six months ending September 30, 2025, IGC Pharma generated revenue of $519,000, down from $684,000 in the same period last year. The company’s total operating loss for this period was $4.8 million, slightly higher than the $4.2 million loss reported in the previous year. The increase in R&D expenses and the planned transition of the Vancouver facility contributed to the overall financial performance. The company’s cash and cash equivalents increased significantly to $1.1 million, up from $405,000 at the end of the previous fiscal year, indicating improved liquidity.

Strategically, IGC Pharma has made notable advancements in its clinical programs and AI initiatives. The company successfully enrolled over 50% of patients in its ongoing Phase 2 clinical trial for IGC-AD1, marking a key operational milestone. Additionally, the company is developing MINT-AD, an AI-driven diagnostic tool aimed at improving early detection of Alzheimer’s disease. The company has also expanded its clinical trial sites internationally, including new locations in Canada and Oklahoma, which may enhance patient recruitment and data collection.

Looking ahead, IGC Pharma remains focused on completing its clinical trials and advancing its AI initiatives. The company plans to continue leveraging its proprietary AI platform to enhance drug discovery and optimize clinical trial design. While the company acknowledges the challenges associated with regulatory approvals and market conditions, it believes that its ongoing investments in R&D and strategic partnerships will position it for future growth. The company is also exploring additional funding opportunities to support its operations and clinical programs, although it cautions that there are no guarantees regarding the success of these efforts.